← Back to all trials
Active Not Recruiting
NCT06540261
The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer
Conditions: Unresectable Colorectal Cancer
Sex: All
Ages: 20 Years – N/A
Healthy volunteers: No
Phase: PHASE1
Enrollment: 65
Sponsor: Ono Pharmaceutical Co., Ltd.
Location: Fujita Health University Hospital Toyoake Aichi-ken
Summary
To confirm the tolerability and safety of combined administration of ONO-7913, ONO-4538 and the standard of care FOLFOX in combination with bevacizumab or cetuximab as first-line treatment in patients with unresectable advanced or recurrent colorectal cancer
Eligibility Criteria
Inclusion Criteria:
1. Unresectable advanced or recurrent colorectal cancer
2. Life expectancy of at least 3 months
3. Patients with ECOG performance status 0 or 1
Exclusion Criteria:
1. Patients with severe complication
2. Patients with multiple primary cancers
Source: ClinicalTrials.gov (NCT06540261). StuddyBuddy aggregates publicly available trial information.
